Tokushima University / Educator and Researcher Directory --- Azuma, Momoyo

Field of Study

○	Medicine

Subject of Study

○

Book / Paper

Academic Paper (Judged Full Paper):

1.	Takashi Bando, Masayuki Chuma, Hirofumi Hamano, Takahiro Niimura, Naoto Okada, Masateru Kondo, Yuki Izumi, Shunsuke Ishida, Toshihiko Yoshioka, Mizuho Asada, Yoshito Zamami, Kenshi Takechi, Mitsuhiro Goda, Koji Miyata, Kenta Yagi, Yuki Izawa-Ishizawa, Momoyo Azuma, Hiroaki Yanagawa, Yoshikazu Tasaki and Keisuke Ishizawa : Concomitant Use of Multiple Nephrotoxins including Renal Hypoperfusion Medications Causes Vancomycin-Associated Nephrotoxicity: Combined Retrospective Analyses of Two Real-World Databases., Acta Medica Okayama, Vol.77, No.6, 595-605, 2023. (Summary) There is a growing concern about the relationship between vancomycin-associated nephrotoxicity (VAN) and concomitant use of nephrotoxins. We examined this relationship by combined retrospective analyses of two real-world databases. Initially, the FDA Adverse Event Reporting System (FAERS) was analyzed for the effects of concomitant use of one or more nephrotoxins on VAN and the types of combinations of nephrotoxins that exacerbate VAN. Next, electronic medical records (EMRs) of patients who received vancomycin (VCM) at Tokushima University Hospital between January 2006 and March 2019 were examined to confirm the FAERS analysis. An elevated reporting odds ratio (ROR) was observed with increases in the number of nephrotoxins administered (VCM + one nephrotoxin, adjusted ROR (95% confidence interval [CI]) 1.67 [1.51-1.85]; VCM + 2 nephrotoxins, adjusted ROR [95% CI] 1.54 [1.37-1.73]) in FAERS. EMRs analysis showed that the number of nephrotoxins was associated with higher incidences of VAN [odds ratio: 1.99; 95% CI: 1.42-2.78]. Overall, concomitant use of nephrotoxins was associated with an increased incidence of VAN, especially when at least one of those nephrotoxins was a renal hypoperfusion medication (furosemide, non-steroidal anti-inflammatory drugs, and vasopressors). The concomitant use of multiple nephrotoxins, especially including renal hypoperfusion medication, should be avoided to prevent VAN. (Keyword) Humans / Vancomycin / Anti-Bacterial Agents / Retrospective Studies / Causality / Acute Kidney Injury (Tokushima University Institutional Repository) ● Metadata: 118742 (Link to Publication Site) ● Publication site (DOI): 10.18926/AMO/66151 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38145933 ● Search Scopus @ Elsevier (PMID): 38145933 ● Search Scopus @ Elsevier (DOI): 10.18926/AMO/66151 (Tokushima University Institutional Repository: 118742, DOI: 10.18926/AMO/66151, PubMed: 38145933)
2.	Momoyo Azuma, Kazunori Oishi, Yukihiro Akeda, Saeko Morino, Yumi Motoki, Masaki Hanibuchi and Yasuhiko Nishioka : Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year., Vaccine, Vol.41, No.5, 1042-1049, 2023. (Summary) The 1.0-y interval provided better booster effects induced by PPSV23 than those of the 0.5-y interval in a sequential administration in pneumococcal vaccine-naïve adults aged 65 years. No difference was found in the safety profile between both intervals. (Keyword) Humans / Antibodies, Bacterial / Double-Blind Method / Immunogenicity, Vaccine / Immunoglobulin G / Pneumococcal Infections / Pneumococcal Vaccines / Streptococcus pneumoniae / Vaccines, Conjugate (Tokushima University Institutional Repository) ● Metadata: 118625 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.vaccine.2022.12.060 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36593171 ● Search Scopus @ Elsevier (PMID): 36593171 ● Search Scopus @ Elsevier (DOI): 10.1016/j.vaccine.2022.12.060 (Tokushima University Institutional Repository: 118625, DOI: 10.1016/j.vaccine.2022.12.060, PubMed: 36593171)
3.	Morito Katsuya, Shimizu Ryota, Ali Hanif, Shimada Akina, Miyazaki Tohru, Takahashi Naoko, Rahman Motiur M., Tsuji Kazuki, Shimozawa Nobuyuki, Michiyasu Nakao, Shigeki Sano, Momoyo Azuma, Nanjundan Meera, Kentaro Kogure and Tamotsu Tanaka : Molecular species profiles of plasma ceramides in different clinical types of X-linked adrenoleukodystrophy, The Journal of Medical Investigation : JMI, Vol.70, No.3.4, 403-410, 2023. (Summary) X-linked adrenoleukodystrophy (X-ALD) is a genetic disorder associated with peroxisomal dysfunction. Patients with this rare disease accumulate very long-chain fatty acids (VLCFAs) in their bodies because of impairment of peroxisomal VLCFA ?-oxidation. Several clinical types of X-ALD, ranging from mild (axonopathy in the spinal cord) to severe (cerebral demyelination), are known. However, the molecular basis for this phenotypic variability remains largely unknown. In this study, we determined plasma ceramide (CER) profile using liquid chromatography-tandem mass spectrometry. We characterized the molecular species profile of CER in the plasma of patients with mild (adrenomyeloneuropathy;AMN) and severe (cerebral) X-ALD. Eleven X-ALD patients (five cerebral, five AMN, and one carrier) and 10 healthy volunteers participated in this study. Elevation of C26:0 CER was found to be a common feature regardless of the clinical types. The level of C26:1 CER was significantly higher in AMN but not in cerebral type, than that in healthy controls. The C26:1 CER level in the cerebral type was significantly lower than that in the AMN type. These results suggest that a high level of C26:0 CER, along with a control level of C26:1 CER, is a characteristic feature of the cerebral type X-ALD. J. Med. Invest. 70 : 403-410, August, 2023. (Keyword) Humans / Adrenoleukodystrophy / Ceramides (Tokushima University Institutional Repository) ● Metadata: 118324 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.403 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37940524 ● Search Scopus @ Elsevier (PMID): 37940524 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.403 (Tokushima University Institutional Repository: 118324, DOI: 10.2152/jmi.70.403, PubMed: 37940524)
4.	Masayuki Chuma, Hirofumi Hamano, Takashi Bando, Masateru Kondo, Naoto Okada, Yuki Izumi, Shunsuke Ishida, Toshihiko Yoshioka, Mizuho Asada, Takahiro Niimura, Yoshito Zamami, Kenshi Takechi, Mitsuhiro Goda, Koji Miyata, Kenta Yagi, Sachiko Kasamo, Yuki Izawa-Ishizawa, Momoyo Azuma, Hiroaki Yanagawa, Yoshikazu Tasaki and Keisuke Ishizawa : Non-recovery of vancomycin-associated nephrotoxicity is related to worsening survival outcomes: Combined retrospective analyses of two real-world databases., Basic & Clinical Pharmacology & Toxicology, Vol.131, No.6, 525-535, 2022. (Summary) There has been growing concern in worsening survival and renal outcomes following vancomycin-associated nephrotoxicity (VAN) onset, but the factors associated with these phenomena remain unclear. To examine these factors, we performed a retrospective study combining the analysis of two real-world databases. Initially, the FDA Adverse Event Reporting System (FAERS) was used to evaluate the relationship between VAN and mortality using odds ratios (ORs) and 95% confidence intervals (CIs). Next, electronic medical records (EMRs) were examined in a more robust cohort for evaluation of the association between renal outcomes and worsening survival using Cox proportional hazards regression models. FAERS analysis revealed a significant correlation between VAN occurrence and increased mortality (OR: 1.30; 95% CI: 1.17-1.46). EMR analysis showed that non-recovery of VAN was associated with increased hospital mortality (hazard ratio [HR]: 4.05; 95% CI: 2.42-6.77) and 1-year mortality (HR: 3.03, 95% CI: 1.98-4.64). The HR for VAN recovery was lower for patients with acute kidney injury (AKI) stage 2 (HR: 0.09; 95% CI: 0.02-0.40). Thus, worsening survival outcomes were associated with non-recovery of VAN, whereby AKI stage 2 was a significant risk factor. Progression to severe VAN should be prevented for better survival outcomes. (Keyword) Humans / Vancomycin / Retrospective Studies / Anti-Bacterial Agents / Acute Kidney Injury / Drug-Related Side Effects and Adverse Reactions / Risk Factors (Link to Publication Site) ● Publication site (DOI): 10.1111/bcpt.13799 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36169161 ● Search Scopus @ Elsevier (PMID): 36169161 ● Search Scopus @ Elsevier (DOI): 10.1111/bcpt.13799 (DOI: 10.1111/bcpt.13799, PubMed: 36169161)
5.	Seryoung Kim, Satomi Masai, Keiji Murakami, Momoyo Azuma, Keiko Kataoka, Mayu Sebe, Kazuya Shimizu, Tomoaki Itayama, Niwooti Whangchai, Kanda Whangchai, Ikko Ihara and Hideaki Maseda : Characteristics of Antibiotic Resistance and Tolerance of Environmentally Endemic ., Antibiotics, Vol.11, No.8, 1120, 2022. (Summary) Antibiotic-resistant bacteria remain a serious public health threat. In order to determine the percentage of antibiotic-resistant and -tolerant cells present and to provide a more detailed infection risk of bacteria present in the environment, an isolation method using a combination of 41 °C culture and specific primers was established to evaluate in the environment. The 50 strains were randomly selected among 110 isolated from the river. The results of antibiotic susceptibility evaluation showed that only 4% of environmental strains were classified as antibiotic-resistant, while 35.7% of clinical strains isolated in the same area were antibiotic-resistant, indicating a clear difference between environmental and clinical strains. However, the percentage of antibiotic-tolerance, an indicator of potential resistance risk for strains that have not become resistant, was 78.8% for clinical strains and 90% for environmental strains, suggesting that , a known cause of nosocomial infections, has a high rate of antibiotic-tolerance even in environmentally derived strains. It suggested that the rate of antibiotic-tolerance is not elicited by the presence or absence of antimicrobial exposure. The combination of established isolation and risk analysis methods presented in this study should provide accurate and efficient information on the risk level of in various regions and samples. (Link to Publication Site) ● Publication site (DOI): 10.3390/antibiotics11081120 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36009989 ● Summary page in Scopus @ Elsevier: 2-s2.0-85137360864 (DOI: 10.3390/antibiotics11081120, PubMed: 36009989, Elsevier: Scopus)
6.	Naoto Okada, Akikazu Murakami, Masami Satou, Shingen Nakamura, Shiroh Fujii, Kimiko Sogabe, Mamiko Takahashi, Asami Okada, Akane Abe, Hideki Fujii, Masahiro Abe, Momoyo Azuma and Keisuke Ishizawa : First reported case of Lachnoanaerobaculum gingivalis bacteremia in an acute myeloid leukemia patient with oral mucositis during high dose chemotherapy., Anaerobe, Vol.76, 2022. (Summary) During chemotherapy in patients with oral mucositis, we should consider the possibility of L. gingivalis bacteremia. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.anaerobe.2022.102610 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35811059 ● Search Scopus @ Elsevier (PMID): 35811059 ● Search Scopus @ Elsevier (DOI): 10.1016/j.anaerobe.2022.102610 (DOI: 10.1016/j.anaerobe.2022.102610, PubMed: 35811059)
7.	Atsushi Tabata, Rina Shirai, Haruka Miki, Yukihiro Nishikawa, Tatsuya Kashima, Tomomi Aoyama, Shu Murakami, Momoyo Azuma, Toshifumi Tomoyasu and Hideaki Nagamune : Hapten-labeled fusion-polymerase chain reaction of multiple marker genes for the application of immunochromatographic test., Journal of Bioscience and Bioengineering, Vol.134, No.1, 70-76, 2022. (Summary) A variety of methods have been reported using polymerase chain reaction (PCR)-based nucleic acid testing (NAT) because of its potential to be used in highly sensitive inspection systems. Among these NATs, fusion-PCR (also called as overlap-extension-PCR) has been focused on this study and adopted to generate the fused amplicon composed of plural marker gene fragments for detection. Generally, conventional agarose gel electrophoresis followed by gel staining is employed to check the PCR results. However, these are time-consuming processes that use specific equipment. To overcome these disadvantages, the immunochromatographic test (ICT) for the detection of PCR amplicons with hapten-labels that were generated by PCR using hapten-labeled primers was also adopted in this study. Based on these concepts, we constructed the systems of hapten-labeled fusion-PCR (HL-FuPCR) followed by ICT (HL-FuPCR-ICT) for the two and three marker genes derived from pathogenic microbe. As a result, we successfully developed a two marker genes system for the pathogenic influenza A virus and a three marker genes system for the penicillin-resistant Streptococcus pneumoniae. These detection systems of HL-FuPCR-ICT are characterized by simple handling and rapid detection within few minutes, and also showed the results as clear lines. Thus, the HL-FuPCR-ICT system introduced in this study has potential for use as a user-friendly inspection tool with the advantages especially in the detection of specific strains or groups expressing the characteristic phenotype(s) such as antibiotic resistance and/or high pathogenicity even in the same species. (Keyword) DNA Primers / Haptens / Immunologic Tests / Polymerase Chain Reaction / Sensitivity and Specificity (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jbiosc.2022.03.006 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35450786 ● Search Scopus @ Elsevier (PMID): 35450786 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jbiosc.2022.03.006 (DOI: 10.1016/j.jbiosc.2022.03.006, PubMed: 35450786)
8.	Tamotsu Tanaka, Kazuya Koyama, Naoko Takahashi, Katsuya Morito, Hanif Ali, Momoyo Azuma, Kozo Kagawa, Hiroshi Kawano, Rumana Yesmin, Mutsumi Aihara and Yasuhiko Nishioka : Lysophosphatidic acid, ceramide 1-phosphate and sphingosine 1-phosphate in peripheral blood of patients with idiophathic pulmonary fibrosis, The Journal of Medical Investigation : JMI, Vol.69, No.3.4, 196-203, 2022. (Summary) Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonias. Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are signaling lipids that evoke growth factor-like responses to many cells. Recent studies revealed the involvement of LPA and S1P in the pathology of IPF. In this study, we determined LPA, S1P and ceramide 1-phosphate (C1P) in peripheral blood plasma of IPF patients, and examined correlation to the vital capacity of lung (VC), an indicator of development of fibrosis. Blood plasma samples were taken from eleven patients with IPF and seven healthy volunteers. The lipids of the sample were extracted and subjected to liquid chromatography-tandem mass spectrometry for analysis. Results showed that there is a significant negative correlation between VC and plasma LPA levels, indicating that IPF patients with advanced fibrosis had higher concentration of LPA in their plasma. Average of S1P levels were significantly higher in IPF patients than those in healthy subjects. Although it is not statistically significant, a similar correlation trend that observed in LPA levels also found between VC and S1P levels. These results indicated that plasma LPA and S1P may be associated with deterioration of pulmonary function of IPF patients. J. Med. Invest. 69 : 196-203, August, 2022. (Keyword) Ceramides / Fibrosis / Humans / Idiopathic Pulmonary Fibrosis / Lysophospholipids / Sphingosine (Tokushima University Institutional Repository) ● Metadata: 117621 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.196 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244770 ● Search Scopus @ Elsevier (PMID): 36244770 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.196 (Tokushima University Institutional Repository: 117621, DOI: 10.2152/jmi.69.196, PubMed: 36244770)
9.	Naoto Okada, Yuki Izumi, Aki Nakamoto, Masayuki Chuma, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, Yoshito Zamami, Momoyo Azuma and Keisuke Ishizawa : Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study., Clinical Therapeutics, Vol.43, No.11, 1910-1920.e3, 2021. (Summary) VIN risk was higher with VT than with VC, even when the AUC was controlled to the guideline-recommended range. These results strongly suggest that VIN prevention may be difficult with AUC-guided vancomycin dosing in patients receiving VT. (Keyword) Acute Kidney Injury / Anti-Bacterial Agents / Bayes Theorem / Cefepime / Drug Therapy, Combination / Humans / Penicillanic Acid / Piperacillin / Piperacillin, Tazobactam Drug Combination / Prevalence / Retrospective Studies / Vancomycin (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clinthera.2021.09.007 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34642081 ● Search Scopus @ Elsevier (PMID): 34642081 ● Search Scopus @ Elsevier (DOI): 10.1016/j.clinthera.2021.09.007 (DOI: 10.1016/j.clinthera.2021.09.007, PubMed: 34642081)
10.	Momoyo Azuma, Keiji Murakami, Rina Murata, Keiko Kataoka, Hideki Fujii, Yoichiro Miyake and Yasuhiko Nishioka : Clinical Significance of Carbapenem-Tolerant Pseudomonas aeruginosa Isolated in the Respiratory Tract, Antibiotics, Vol.9, No.9, 2020. (Summary) infections. (Tokushima University Institutional Repository) ● Metadata: 116480 (Link to Publication Site) ● Publication site (DOI): 10.3390/antibiotics9090626 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32967210 ● Search Scopus @ Elsevier (PMID): 32967210 ● Search Scopus @ Elsevier (DOI): 10.3390/antibiotics9090626 (Tokushima University Institutional Repository: 116480, DOI: 10.3390/antibiotics9090626, PubMed: 32967210)
11.	Shuichi Abe, Seidai Satou, Yoshinori Aono, Momoyo Azuma, Masami Kishi, Koyama Kazuya, Takahashi Naoki, Kozo Kagawa, Hiroshi Kawano and Yasuhiko Nishioka : Functional analysis of human fibrocytes derived from monocytes reveals their profibrotic phenotype through paracrine effects, The Journal of Medical Investigation : JMI, Vol.67, No.1.2, 102-112, 2020. (Summary) Fibrocytes, which are bone marrow-derived collagen-producing cells, were reported to play a role in the pathogenesis of pulmonary fibrosis. However, their function in pulmonary fibrosis is unclear. We analyzed their function compared with that of monocytes and localization in fibrotic tissues in patients with idiopathic pulmonary fibrosis (IPF). We compared the gene expression profile of monocyte-derived fibrocytes with that of monocytes by microarray analysis. Proliferation and differentiation into myofibroblasts were examined by 3H-thymidine incorporation assay and Western blotting. We measured the level of growth factors in the culture supernatant of fibrocytes by ELISA. The localization of fibrocytes in lung tissues of patients with IPF was determined by immunofluorescence staining. Compared with monocytes, fibrocytes had higher expression of extracellular matrix- and growth factor-encoding genes, including PDGF-B, FGF-2 and VEGF-B. Although fibrocytes did not proliferate in response to PDGF, co-culture of fibrocytes stimulated the growth of lung fibroblasts through the production of PDGF-BB. In the lung of IPF patients, CD45+Collagen-I+FSP-1+ cells, which have a similar phenotype to fibrocytes, were detected and co-stained with anti-PDGF antibody. This study suggested that fibrocytes function in pulmonary fibrosis partly by producing PDGF in the lungs of IPF patients. J. Med. Invest. 67 : 102-112, February, 2020. (Tokushima University Institutional Repository) ● Metadata: 114734 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.102 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32378592 ● Search Scopus @ Elsevier (PMID): 32378592 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.102 (Tokushima University Institutional Repository: 114734, DOI: 10.2152/jmi.67.102, PubMed: 32378592)
12.	Maria Ulfa, Momoyo Azuma, Masami Satou, Takaaki Shimohata, Shiho Fukushima, Junko Kido, Mariko Nakamoto, Takashi Uebanso, Kazuaki Mawatari, Takahiro Emoto, Masatake Akutagawa, Yohsuke Kinouchi and Akira Takahashi : Inactivation of Extended-spectrum β-Lactamase (ESBL)-producing Escherichia Coli by UVA-LED Irradiation System., The Journal of Medical Investigation : JMI, Vol.67, No.1-2, 163-169, 2020. (Summary) The prevalence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli is increasing rapidly and spreading worldwide, particularly in Asia, compared to other regions. In the last ten years, in our hospital, in particular, there has been a < 30% increase. To prevent the spread of ESBL in hospitals and the community, the ultraviolet (UV) A-light-emitting diode (LED) irradiation device was used to inactivate ESBL-E. coli in human livestock and the environment. ESBL-E. coli and E. coli bacterial samples were collected from patients at Tokushima University Hospital (Tokushima City, Japan). The UVA-LED irradiation system had 365 nm single wavelength, and the current of the circuit was set to 0.23 or 0.50 A consistently. Results demonstrated that UVA-LED was useful for the inactivation of ESBL-E. coli and E. coli. The minimum energy dosage required to inactivate ESBL-E. coli and E. coli was 40.76 J/cm2 (45 min) in the first type of UVA-LED and 38.85 J/cm2 (5 min) in the second type. There were no significant differences between ESBL-E. coli and E. coli. The inactivation of ESBL-E. coli was dependent on energy. These findings suggest that UVA-LED with 365 nm single wavelength could be useful for surface decontamination in healthcare facilities. J. Med. Invest. 67 : 163-169, February, 2020. (Tokushima University Institutional Repository) ● Metadata: 114642 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.163 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32378601 ● Summary page in Scopus @ Elsevier: 2-s2.0-85084329310 (Tokushima University Institutional Repository: 114642, DOI: 10.2152/jmi.67.163, PubMed: 32378601, Elsevier: Scopus)
13.	Naoto Okada, Masayuki Chuma, Momoyo Azuma, Shingen Nakamura, Hirokazu Miki, Hirofumi Hamano, Mitsuhiro Goda, Kenshi Takechi, Yoshito Zamami, Masahiro Abe and Keisuke Ishizawa : Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study., European Journal of Clinical Pharmacology, Vol.75, No.12, 1695-1704, 2019. (Summary) We retrospectively analysed 150 haematologic patients to whom VCM was administered between April 2010 and March 2018 at Tokushima University Hospital. VCM-induced AKI was defined according to Kidney Disease Improving Global Outcomes (KDIGO) criteria. Multivariate logistic regression analyses were performed to identify risk factors for VCM-induced AKI. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00228-019-02756-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31511938 ● Search Scopus @ Elsevier (PMID): 31511938 ● Search Scopus @ Elsevier (DOI): 10.1007/s00228-019-02756-4 (DOI: 10.1007/s00228-019-02756-4, PubMed: 31511938)
14.	Hiroyasu Okazaki, Seidai Satou, Kazuya Koyama, Shun Morizumi, Shuichi Abe, Momoyo Azuma, Yajuan Chen, Hisatsugu Goto, Yoshinori Aono, Hirohisa Ogawa, Kozo Kagawa, Haruka Nishimura, Hiroshi Kawano, Yuko Toyoda, Hisanori Uehara, Hiroyuki Kouji and Yasuhiko Nishioka : The novel inhibitor PRI-724 for Wnt/β-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice., Experimental Lung Research, Vol.45, No.7, 188-199, 2019. (Summary) These results suggest that the β-catenin/CBP inhibitor PRI-724 is a potent antifibrotic agent that acts by modulating the activity of macrophages in the lungs. (Tokushima University Institutional Repository) ● Metadata: 113984 (Link to Publication Site) ● Publication site (DOI): 10.1080/01902148.2019.1638466 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31298961 ● Summary page in Scopus @ Elsevier: 2-s2.0-85068899202 (Tokushima University Institutional Repository: 113984, DOI: 10.1080/01902148.2019.1638466, PubMed: 31298961, Elsevier: Scopus)
15.	Masami Kishi, Yoshinori Aono, Seidai Satou, Kazuya Koyama, Momoyo Azuma, Shuichi Abe, Hiroshi Kawano, Jun Kishi, Yuko Toyoda, Hiroyasu Okazaki, Hirohisa Ogawa, Hisanori Uehara and Yasuhiko Nishioka : Blockade of platelet-derived growth factor receptor-β, not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice., PLoS ONE, Vol.13, No.12, 2018. (Summary) Platelet-derived growth factor (PDGF) has been implicated in the pathogenesis of pulmonary fibrosis. Nintedanib, a multi-kinase inhibitor that targets several tyrosine kinases, including PDGF receptor (PDGFR), was recently approved as an anti-fibrotic agent to reduce the deterioration of FVC in patients with idiopathic pulmonary fibrosis (IPF). However, the effects of PDGFR-α or -β on pulmonary fibrosis remain unclear. In an attempt to clarify their effects, we herein used blocking antibodies specific for PDGFR-α (APA5) and -β (APB5) in a bleomycin (BLM)-induced pulmonary fibrosis mouse model. The effects of these treatments on the growth of lung fibroblasts were examined using the 3H-thymidine incorporation assay in vitro. The anti-fibrotic effects of these antibodies were investigated with the Ashcroft score and collagen content of lungs treated with BLM. Their effects on inflammatory cells in the lungs were also analyzed using bronchoalveolar lavage fluid. We investigated damage to epithelial cells and the proliferation of fibroblasts in the lungs. APA5 and APB5 inhibited the phosphorylation of PDGFR-α and -β as well as the proliferation of lung fibroblasts induced by PDGF-AA and BB. The administration of APB5, but not APA5 effectively inhibited BLM-induced pulmonary fibrosis in mice. Apoptosis and the proliferation of epithelial cells and fibroblasts were significantly decreased by the treatment with APB5, but not by APA5. The late treatment with APB5 also ameliorated fibrosis in lungs treated with BLM. These results suggest that PDGFR-α and -β exert different effects on BLM-induced pulmonary fibrosis in mice. A specific approach using the blocking antibody for PDGFR-β may be useful for the treatment of pulmonary fibrosis. (Tokushima University Institutional Repository) ● Metadata: 113268 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0209786 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30596712 ● Search Scopus @ Elsevier (PMID): 30596712 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0209786 (Tokushima University Institutional Repository: 113268, DOI: 10.1371/journal.pone.0209786, PubMed: 30596712)
16.	Naoto Okada, Momoyo Azuma, Masaki Imanishi, Yoshito Zamami, Yasushi Kirino, Toshimi Nakamura, Kazuhiko Teraoka, Masahiro Abe and Keisuke Ishizawa : Potential Usefulness of Early Potassium Supplementation for Preventing Severe Hypokalemia Induced by Liposomal Amphotericin B in Hematologic Patients: A Retrospective Study., Clinical Therapeutics, Vol.40, No.2, 252-260, 2018. (Summary) This study showed that starting administration of a potassium formulation within 2 days from the start of L-AMB administration was a risk reduction factor for L-AMB-induced hypokalemia. This finding indicates that early potassium supplementation should be incorporated into the regimen of hypokalemia management when L-AMB is used. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clinthera.2017.12.006 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29305017 ● Search Scopus @ Elsevier (PMID): 29305017 ● Search Scopus @ Elsevier (DOI): 10.1016/j.clinthera.2017.12.006 (DOI: 10.1016/j.clinthera.2017.12.006, PubMed: 29305017)
17.	Naoto Okada, Shuji Fushitani, Momoyo Azuma, Shingen Nakamura, Toshimi Nakamura, Kazuhiko Teraoka, Hiroyoshi Watanabe, Masahiro Abe, Kazuyoshi Kawazoe and Keisuke Ishizawa : Clinical evaluation of pharmacist interventions in patients treated with anti-methicillin-resistant Staphylococcus aureus agents in a hematological ward, Biological & Pharmaceutical Bulletin, Vol.39, No.2, 295-300, 2015. (Summary) The therapeutic effects of anti-methicillin-resistant Staphylococcus aureus (MRSA) agents, vancomycin (VCM), teicoplanin (TEIC), and arbekacin (ABK), depend on their concentrations in blood. Therefore, therapeutic drug monitoring (TDM) is important when these antibiotics are used. In the hematological ward at Tokushima University Hospital, pharmacists have ordered the measurement of blood VCM, TEIC, and ABK concentrations to promote the use of TDM in accordance with an agreed protocol since 2013. Moreover, the infection control team includes several medical disciplines and has advised on the optimal treatment using VCM, TEIC, and ABK since 2013. This study aimed to investigate the clinical effectiveness of these pharmacist interventions. We retrospectively studied 145 cases in which patients were treated with VCM, TEIC, or ABK between January 2012 and December 2013 in the hematological ward at Tokushima University Hospital. The patients were divided into a control group (71 cases) and an intervention group (74 cases), and their clinical outcomes were compared. The rate of achievement of effective drug concentrations significantly increased in the intervention group (74%), compared to the rate in the control group (55%). Moreover, univariate and multivariate Cox proportional hazard regression revealed that pharmacist intervention and appropriate concentrations of anti-MRSA agents were independent factors associated with reduced hospitalization periods in patients with lymphoma. Our study revealed that proactive pharmacist intervention may improve the therapeutic effect of anti-MRSA agents in hematology ward patients. (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b15-00774 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26830489 ● Search Scopus @ Elsevier (PMID): 26830489 ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b15-00774 (DOI: 10.1248/bpb.b15-00774, PubMed: 26830489)
18.	Yoshinori Aono, Masami Kishi, Yuki Yokota, Momoyo Azuma, Katsuhiro Kinoshita, Akio Takezaki, Seidai Sato, Hiroshi Kawano, Jun Kishi, Hisatsugu Goto, Hisanori Uehara, Keisuke Izumi and Yasuhiko Nishioka : Role of PDGF/PDGFR axis in the trafficking of circulating fibrocytes in pulmonary fibrosis, American Journal of Respiratory Cell and Molecular Biology, Vol.51, No.6, 793-801, 2014. (Summary) Circulating fibrocytes have been reported to migrate into the injured lungs, and contribute to fibrogenesis via CXCL12-CXCR4 axis. In contrast, we report that imatinib mesylate prevented bleomycin (BLM)-induced pulmonary fibrosis in mice by inhibiting platelet-derived growth factor receptor (PDGFR), even when it was administered only in the early phase. The goal of this study was to test the hypothesis that platelet-derived growth factor (PDGF) might directly contribute to the migration of fibrocytes to the injured lungs. PDGFR expression in fibrocytes was examined by flow cytometry and RT-PCR. The migration of fibrocytes was evaluated by using a chemotaxis assay for human fibrocytes isolated from peripheral blood. The numbers of fibrocytes triple-stained for CD45, collagen-1, and CXCR4 were also examined in lung digests of BLM-treated mice. PDGFR mRNA levels in fibrocytes isolated from patients with idiopathic pulmonary fibrosis were investigated by real-time PCR. Fibrocytes expressed both PDGFR-α and -β, and migrated in response to PDGFs. PDGFR inhibitors (imatinib, PDGFR-blocking antibodies) suppressed fibrocyte migration in vitro, and reduced the number of fibrocytes in the lungs of BLM-treated mice. PDGF-BB was a stronger chemoattractant than the other PDGFs in vitro, and anti-PDGFR-β-blocking antibody decreased the numbers of fibrocytes in the lungs compared with anti-PDGFR-α antibody in vivo. Marked expression of PDGFR-β was observed in fibrocytes from patients with idiopathic pulmonary fibrosis compared with healthy subjects. These results suggest that PDGF directly functions as a strong chemoattractant for fibrocytes. In particular, the PDGF-BB-PDGFR-β biological axis might play a critical role in fibrocyte migration into the fibrotic lungs. (Keyword) Animals / Benzamides / Case-Control Studies / Chemotaxis / Drug Evaluation, Preclinical / Female / Humans / Injections, Intraperitoneal / Mice, Inbred C57BL / Piperazines / Platelet-Derived Growth Factor / pulmonary fibrosis / Pyrimidines / Receptor, Platelet-Derived Growth Factor beta / Receptors, CXCR4 / signal transduction (Link to Publication Site) ● Publication site (DOI): 10.1165/rcmb.2013-0455OC (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24885373 ● Summary page in Scopus @ Elsevier: 2-s2.0-84918792291 (DOI: 10.1165/rcmb.2013-0455OC, PubMed: 24885373, Elsevier: Scopus)
19.	Katsuhiro Kinoshita, Yoshinori Aono, 竹崎彰夫, 岡﨑弘泰, 吉嶋輝美, 岸昌美, Momoyo Azuma, Jun Kishi, Keisuke Izumi and Yasuhiko Nishioka : ブレオマイシン肺線維症モデルにおけるFAKシグナル阻害薬の抗線維化効果, Respiratory Molecular Medicine, Vol.18, No.1, 154-157, 2014. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520291855460530048 (CiNii: 1520291855460530048)
20.	Momoyo Azuma, Asami NAKASO, Saori NISHINO, Tomoko TAKAGAI, Shoji Sakiyama, Shinsuke Katoh and Yasuhiko Nishioka : Use of Ethanol-Based Hand Rub Foams in The Clinical Setting, Japanese Journal of Infection Prevention and Control, Vol.28, No.6, 342-347, 2013. (Summary) Alcohol-based hand rubs are recommended for use by healthcare staff worldwide. In addition to gel and liquid rubs, ethanol-based foam is available for hand hygiene. Ethanol-based foam was launched as the first alcohol-based foaming hand rub available in Japan in June 2011. Ethanol-based foam has gained attention among healthcare staff because ethanol-based foam does not drip from the hands, and allows good visual coverage. This study compared the effectiveness of ethanol-based gel and foam for bacterial removal and the percentage of areas covered with gel or foam. The Parm-Stamp Test was used to prove that ethanol-based foam has the same efficacy against bacteria as gel. To examine if the hands were fully covered with gel or foam, we used the Black Lights device and fluorescence powder. The results showed that the ethanol-based foam provided significantly improved coverage compared with the gel. According to the questionnaire results, ethanol-based foam has a lot of unique benefits, such as no dripping, easy spreading, good visual coverage, and no sticky feeling. Due to the effective cleaning with excellent skin feel during and after use, ethanol-based hand rub foam is very useful in the clinical setting for hand hygiene among healthcare workers. (Link to Publication Site) ● Publication site (DOI): 10.4058/jsei.28.342 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205297098240 ● Search Scopus @ Elsevier (DOI): 10.4058/jsei.28.342 (DOI: 10.4058/jsei.28.342, CiNii: 1390001205297098240)
21.	Katsuhiro Kinoshita, Yoshinori Aono, Momoyo Azuma, Jun Kishi, Akio Takezaki, Masami Kishi, Hideki Makino, Hiroyasu Okazaki, Hisanori Uehara, Keisuke Izumi, Saburo Sone and Yasuhiko Nishioka : Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice., American Journal of Respiratory Cell and Molecular Biology, Vol.49, No.4, 536-543, 2013. (Summary) Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase involved in various biological functions, including cell survival, proliferation, migration, and adhesion. FAK is an essential factor for transforming growth factor to induce myofibroblast differentiation. In the present study, we investigated whether the targeted inhibition of FAK by using a specific inhibitor, TAE226, has the potential to regulate pulmonary fibrosis. TAE226 showed inhibitory activity of autophosphorylation of FAK at tyrosine 397 in lung fibroblasts. The addition of TAE226 inhibited the proliferation of lung fibroblasts in response to various growth factors, including platelet-derived growth factor and insulin-like growth factor I, in vitro. TAE226 strongly suppressed the production of type I collagen by lung fibroblasts. Furthermore, treatment of fibroblasts with TAE226 reduced the expression of -smooth muscle actin induced by transforming growth factor , indicating the inhibition of differentiation of fibroblasts to myofibroblasts. Administration of TAE226 ameliorated the pulmonary fibrosis induced by bleomycin in mice even when used late in the treatment. The number of proliferating mesenchymal cells was reduced in the lungs of TAE226-treated mice. These data suggest that FAK signal plays a significant role in the progression of pulmonary fibrosis and that it can become a promising target for therapeutic approaches to pulmonary fibrosis. (Keyword) Actins / Animals / Bleomycin / Cell Differentiation / Cell Proliferation / Collagen Type I / DNA / Epithelial Cells / Female / Fibroblasts / Focal Adhesion Kinase 1 / Insulin-Like Growth Factor I / Mesenchymal Stromal Cells / Mice / Mice, Inbred C57BL / Morpholines / Myofibroblasts / Phosphorylation / Platelet-Derived Growth Factor / Protein Kinase Inhibitors / Pulmonary Fibrosis / Transforming Growth Factor beta / Tyrosine (Tokushima University Institutional Repository) ● Metadata: 106054 (Link to Publication Site) ● Publication site (DOI): 10.1165/rcmb.2012-0277OC (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23642017 ● Search Scopus @ Elsevier (PMID): 23642017 ● Search Scopus @ Elsevier (DOI): 10.1165/rcmb.2012-0277OC (Tokushima University Institutional Repository: 106054, DOI: 10.1165/rcmb.2012-0277OC, PubMed: 23642017)
22.	Hideki Makino, Yoshinori Aono, Momoyo Azuma, Masami Kishi, Yuki Yokota, Katsuhiro Kinoshita, Akio Takezaki, Jun Kishi, Hiroshi Kawano, Hirohisa Ogawa, Hisanori Uehara, Keisuke Izumi, Saburo Sone and Yasuhiko Nishioka : Antifibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice., The Journal of Medical Investigation : JMI, Vol.60, No.1-2, 127-137, 2013. (Summary) Circulating fibrocytes had been reported to migrate into the injured lungs, and contribute to fibrogenesis via chemokine-chemokine receptor systems including CXCL12-CXCR4 axis. Here we hypothesized that blockade of CXCR4 might inhibit the migration of fibrocytes to the injured lungs and the subsequent pulmonary fibrosis. To explore the antifibrotic effects of blockade of CXCR4, we used a specific antagonist for CXCR4, AMD3100, in bleomycin-induced pulmonary fibrosis model in mice. Administration of AMD3100 significantly improved the loss of body weight of mice treated with bleomycin, and inhibited the fibrotic lesion in subpleural areas of the lungs. The quantitative analysis demonstrated that treatment with AMD3100 reduced the collagen content and fibrotic score (Aschcroft score) in the lungs. Although AMD3100 did not affect cell classification in bronchoalveolar lavage fluid on day 7, the percentage of lymphocytes was reduced by AMD3100 on day 14. AMD3100 directly inhibited the migration of human fibrocytes in response to CXCL12 in vitro, and reduced the trafficking of fibrocytes into the lungs treated with bleocmycin in vivo. These results suggest that the blockade of CXCR4 might be useful strategy for therapy of patients with pulmonary fibrosis via inhibiting the migration of circulating fibrocytes. (Tokushima University Institutional Repository) ● Metadata: 106047 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.127 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23614921 ● Search Scopus @ Elsevier (PMID): 23614921 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.60.127 (Tokushima University Institutional Repository: 106047, DOI: 10.2152/jmi.60.127, PubMed: 23614921)
23.	Rentsenkhand Batmunkh, Yasuhiko Nishioka, Yoshinori Aono, Momoyo Azuma, Katsuhiro Kinoshita, Jun Kishi, Hideki Makino, Masami Kishi, Akio Takezaki and Saburo Sone : CCN6 as a profibrotic mediator that stimulates the proliferation of lung fibroblasts via the integrin β1/focal adhesion kinase pathway., The Journal of Medical Investigation : JMI, Vol.58, No.3-4, 188-196, 2011. (Summary) Idiopathic pulmonary fibrosis is a progressive and lethal disease of the lung that is characterized by the proliferation of fibroblasts and increased deposition of the extracellular matrix. The CCN6/WISP-3 is a member of the CCN family of matricellular proteins, which consists of six members that are involved in many vital biological functions. However, the regulation of lung fibroblasts mediated by CCN6 protein has not been fully elucidated. Here, we demonstrated that CCN6 induced the proliferation of lung fibroblasts by binding to integrin β1, leading to the phosphorylation of FAK(Y397). Furthermore, CCN6 showed a weak, but significant, ability to stimulate the expression of fibronectin. CCN6 was highly expressed in the lung tissues of mice treated with bleomycin. Our results suggest that CCN6 plays a role in the fibrogenesis of the lungs mainly by stimulating the growth of lung fibroblasts and is a potential target for the treatment of pulmonary fibrosis. (Keyword) Animals / Antigens, CD29 / CCN Intercellular Signaling Proteins / Cell Proliferation / Extracellular Matrix Proteins / Female / Fibroblasts / Focal Adhesion Protein-Tyrosine Kinases / Humans / Lung / Mice / Mice, Inbred C57BL / pulmonary fibrosis / signal transduction (Tokushima University Institutional Repository) ● Metadata: 83833 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.58.188 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21921419 ● Search Scopus @ Elsevier (PMID): 21921419 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.58.188 (Tokushima University Institutional Repository: 83833, DOI: 10.2152/jmi.58.188, PubMed: 21921419)
24.	Jun Kishi, Yasuhiko Nishioka, Tomomi Kuwahara, Souji Kakiuchi, Momoyo Azuma, Yoshinori Aono, Hideki Makino, Katsuhiro Kinoshita, Masami Kishi, R Batmunkh, Hisanori Uehara, Keisuke Izumi and Saburo Sone : Blockade of Th1 chemokine receptors ameliorates pulmonary granulomatosis in mice., The European Respiratory Journal, Vol.38, No.2, 415-424, 2011. (Summary) Sarcoidosis is a granulomatous disease of unknown aetiology. We identified immunological targets for the treatment of pulmonary granulomatosis using a murine model generated with Propionibacterium acnes. Sensitisation and challenge using heat-killed P. acnes and dendritic cells (DCs) were performed to produce pulmonary granulomatosis in C57BL/6 mice. Immunological analyses using ELISA as well as cDNA microarray analysis were used to search for cytokines or chemokines associated with the formation of granulomas in the lungs. Co-administration of P. acnes and DCs reproducibly induced the formation of pulmonary granulomas, which resembled sarcoid granulomas. The cDNA microarray assay demonstrated that the gene expression of CXCL9 and CXCL10, ligands for CXCR3, and of CCL4, a ligand for CCR5, was strongly upregulated during granulomatosis. ELISA confirmed that levels of CXCL9 and CXCL10 as well as T-helper (Th)1 cytokines and chemokines including tumour necrosis factor-α and interferon-γ were elevated in bronchoalveolar lavage fluid (BALF). The blockade of Th1 chemokine receptors using TAK-779, a dual blocker for CXCR3 and CCR5, led to reduced numbers of CXCR3+CD4+ and CCR5+CD4+ T-cells in BALF. Furthermore, administration of TAK-779 ameliorated the granulomatosis. The targeted inhibition of Th1 chemokines might be useful for inhibiting Th1-biased granulomatous diseases, including sarcoidosis. (Keyword) Amides / Animals / Bronchoalveolar Lavage Fluid / CD4-Positive T-Lymphocytes / Chemokine CCL4 / Chemokine CXCL10 / Chemokine CXCL9 / Dendritic Cells / Female / Gene Expression Regulation, Bacterial / Granuloma / Interferon-gamma / Lung Diseases / Mice / Mice, Inbred C57BL / Propionibacterium acnes / Quaternary Ammonium Compounds / Receptors, CXCR3 / Receptors, Chemokine / Th1 Cells / Tumor Necrosis Factor-alpha (Link to Publication Site) ● Publication site (DOI): 10.1183/09031936.00070610 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21273392 ● Summary page in Scopus @ Elsevier: 2-s2.0-80051520852 (DOI: 10.1183/09031936.00070610, PubMed: 21273392, Elsevier: Scopus)
25.	組橋由記, Masaki Hanibuchi, 富本英樹, Momoyo Azuma, 兼松貴則, Souji Kakiuchi, Hisatsugu Goto, 多田浩也, Yasuhiko Nishioka and Saburo Sone : 非小細胞肺癌患者のpatient-reported outcome(PRO)評価法の現状と問題点 ―第III 相臨床試験論文のreview―, Japanese Journal of Lung Cancer, Vol.50, No.6, 791-802, 2010. (Summary) Background. Recently, much attention has been paid to patient-reported outcomes (PRO) as self-administered assessment instruments in the quality of life evaluation of cancer patients. Objective and Methods. In the present study, we reviewed a total of 24 published articles (1999 through 2007) which reported phase III clinical trials for non-small-cell lung cancer, all of which set PRO assessment as one of the study endpoints. We evaluated the questionnaires used for PRO assessment, assessment intervals and patient compliance with PRO assessment in each trial. Several kinds of questionnaires were used in most PRO assessment trials. Results. The European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) was used in 17 out of 24 trials. PRO was commonly assessed before each course of chemotherapy, at the end of chemotherapy and 1-3 months after treatment cessation. Patient compliance at the final assessment had significantly deteriorated compared with baseline PRO assessment, presumably due to the increment of missing data. Conclusion. Further studies which evaluate the problems of PRO assessment as a surrogate marker of therapeutic efficacy in lung cancer patients are warranted. (Keyword) lung cancer / 癌薬物療法 / Patient-reported outcome(PRO) / QOL / Chemotherapy (Link to Publication Site) ● Publication site (DOI): 10.2482/haigan.50.791 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001204681018368 ● Summary page in Scopus @ Elsevier: 2-s2.0-78650334692 (DOI: 10.2482/haigan.50.791, CiNii: 1390001204681018368, Elsevier: Scopus)
26.	Takanori Kanematsu, Masaki Hanibuchi, Hideki Tomimoto, Shoji Sakiyama, Koichiro Kenzaki, Kazuya Kondo, Bando Hiroyasu, Haku Takashi, Yoneda Kazuo, Hirose Toshiyuki, Toyoda Yuko, Hisatsugu Goto, Sakaguchi Satoshi, Katsuhiro Kinoshita, Momoyo Azuma, Kakiuchi Soji, Jun Kishi, Masahiko Azuma, Tada Hiroya, Sumitomo Masayuki, Yasuhiko Nishioka, Seiji Yano and Saburo Sone : Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan, The Journal of Medical Investigation : JMI, Vol.57, No.3,4, 326-333, 2010. (Summary) Lung cancer is the leading cause of malignancy-related death worldwide. In the present study, we reviewed the epidemiologic and clinical features of lung cancer in Tokushima Prefecture, Japan. Between January 1999 and December 2009, 2,183 patients with lung cancer were enrolled in this study. One thousand five hundred ninety-one (73%) patients were male and 592 (27%) patients were female. Median age was 70 years, with a range of 15-93 years. Seventy-six percent of patients had smoking history. One thousand nine hundred five (87%) patients were non-small cell lung cancer and the predominant histological type was adenocarcinoma (51%). Among all 2,183 patients, 702 (32%) belonged to elderly population. Four hundred seventy-one (22%), 213 (10%), 24 (1%), 116 (5%), 238 (11%), 370 (17%) and 678 (31%) patients had stage IA, IB, IIA, IIB, IIIA, IIIB and IV lung cancer, respectively. In Tokushima University Hospital, 516 (29%), 191 (11%), 58 (3%), 755 (43%) and 216 (12%) patients were initially treated with chemotherapy, chemo-radiotherapy, thoracic radiotherapy, operation and best supportive care, respectively. The median time to progression (TTP) and the median survival time (MST) of patients treated with chemotherapy and chemo-radiotherapy were 3.5 months, 13.0 months and 7.0 months, 18.0 months, respectively. The median TTP and the MST of 33 elderly patients treated with chemotherapy were 3.3 months and 18.0 months, respectively, which were comparable with those of total population. These results indicated the benefit of chemotherapy in elderly patients with advanced lung cancer by proper selection. (Keyword) Adolescent / Adult / Age Factors / Aged / Aged, 80 and over / Carcinoma, Non-Small-Cell Lung / Carcinoma, Small Cell / Female / Humans / Japan / Kaplan-Meier Estimate / Lung Neoplasms / Male / Middle Aged / Risk Factors / smoking / Young Adult (Tokushima University Institutional Repository) ● Metadata: 79184 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.57.326 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20847534 ● Summary page in Scopus @ Elsevier: 2-s2.0-78649676894 (Tokushima University Institutional Repository: 79184, DOI: 10.2152/jmi.57.326, PubMed: 20847534, Elsevier: Scopus)

Review, Commentary:

1.	Momoyo Azuma and Keiji Murakami : 感染症とは, 歯界展望(別冊), 167-172, May 2014.
2.	Yasuhiko Nishioka, Momoyo Azuma, Masami Kishi and Yoshinori Aono : Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis., The Journal of Medical Investigation : JMI, Vol.60, No.3-4, 175-183, Aug. 2013. (Summary) Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal lung disease characterized by the proliferation of fibroblasts and deposition of extracellular matrix. Since the prognosis of IPF is still poor, novel therapeutic modalities are strongly required. For this reason, to find molecular target for therapy of IPF is of much importance. The recent understanding of pathogenesis in IPF indicates the critical role of alveolar epithelial type II cells (AECII) and fibroblasts. Although the detailed mechanisms involved in IPF is still unclear, various profibrotic mediators which are produced by the injured AECII are thought to play a role in the progression of pulmonary fibrosis via stimulating fibroblasts. Among them, platelet-derived growth factor (PDGF) is one of critical growth factors by stimulating the proliferation and migration of fibroblasts. In this review, we discuss the role of PDGF in pulmonary fibrosis and the possibility as a therapeutic target for IPF. (Tokushima University Institutional Repository) ● Metadata: 106354 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.175 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24190033 ● Search Scopus @ Elsevier (PMID): 24190033 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.60.175 (Tokushima University Institutional Repository: 106354, DOI: 10.2152/jmi.60.175, PubMed: 24190033)
3.	Katsuhiro Kinoshita, Yasuhiko Nishioka, 岸昌美, 竹﨑彰夫, Yoshinori Aono, Momoyo Azuma, Jun Kishi, Hisanori Uehara, Keisuke Izumi and Saburo Sone : FAKシグナルの肺線維化における役割-ブレオマイシン肺線維症モデルでの検討, Respiratory Molecular Medicine, Vol.15, No.1, 124-127, 2011.
4.	Yasuhiko Nishioka, Yoshinori Aono, Momoyo Azuma and Jun Kishi : Imatinib(Glivec®), Respiration & Circulation, Vol.58, No.4, 389-395, 2010. (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-77950638413 (Elsevier: Scopus)
5.	Yasuhiko Nishioka, Momoyo Azuma, Susumu Kagawa and Saburo Sone : Basic and clinical aspects of severe acute respiratory syndrome (SARS) : infection control in Tokushima University Hospital, Shikoku Acta Medica, Vol.60, No.5-6, 112-117, 2004. (Keyword) SARS / coronavirus / PPE / infection control (Tokushima University Institutional Repository) ● Metadata: 44166 (Tokushima University Institutional Repository: 44166)

Proceeding of International Conference:

1.	Ulfa Maria, Takaaki Shimohata, Momoyo Azuma, Masami Sato, Shiho Fukushima, Takashi Uebanso, Kazuaki Mawatari, Masatake Akutagawa and Yohsuke Kinouchi : UVA-LED irradiation system as non-antibiotic approach to inactivation of pathogenic bacteria associated infectious disease, 54th US-Japan Cooperative Medical Sciences Program Conference on cholera and Other Bacterial Enteric Infections, Dec. 2019.
2.	Shingen Nakamura and Momoyo Azuma : Pseudo-outbreak of Mycobacterium chimaera in hematopoietic stem cell transplantation center due to sterile hand-washing machine, ID week 2016, Vol.3, New Orleans, Oct. 2016. (Link to Publication Site) ● Publication site (DOI): 10.1093/ofid/ofw172.1105 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1093/ofid/ofw172.1105 (DOI: 10.1093/ofid/ofw172.1105)
3.	Seidai Satou, Hisatsugu Goto, Shuichi Abe, Masami Kishi, Katsuhiro Kinoshita, Momoyo Azuma, Akio Takezaki, Jun Kishi, Yoshinori Aono, Masaki Hanibuchi and Yasuhiko Nishioka : Effect of Nintedanib (BIBF1120) on fibrocyte-induced fibroblast activation, ATS 2014 International Conference, San Diego, May 2014.
4.	Katsuhiro Kinoshita, Yoshinori Aono, Hisatsugu Goto, Momoyo Azuma, Takezaki Akio, Yoshijima Terumi, Kishi Masami, Jun Kishi, Yuko Toyoda, Hiroshi Kawano, Abe Shuichi, Toshifumi Tezuka, Hisanori Uehara, Keisuke Izumi and Yasuhiko Nishioka : Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice., 18th Congress of the Asian Pacific Society of Respirology, Yokohama, Nov. 2013.
5.	Momoyo Azuma, Keiji Murakami, Katuhiko Hirota, Tsuneko Ono, Yoichiro Miyake and Yasuhiko Nishioka : The relationship between antibiotic tolerance and severity of clinical isolated Pseudomonas aeruginosa in respiratory disease patients, The28th International Congress of Chemotherapy and Infection and the 14th Asia-pacific Society of Clinical Microbiology and Infection, 横浜, Jun. 2013.
6.	Keiji Murakami, Momoyo Azuma, Katsuhiko Hirota, Tsuneko Ono, Nishida Yasuhiko and Yoichiro Miyake : The correlation between antibiotic tolerance and virulence of Pseudomonas aeruginosa clinical isolates, 28th International Congress of Chemoteherap and Infection, Yokohama, Jun. 2013.
7.	Katsuhiro Kinoshita, Yasuhiko Nishioka, Masami Kishi, Momoyo Azuma, Yoshinori Aono, Hisanori Uehara, Akio Takezaki, S. Hatakeyama, E. Kawahara and Saburo Sone : Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice., ATS 2011 International Conference, Denver, May 2011.
8.	Momoyo Azuma, Yasuhiko Nishioka, El-morshedy Mohammed Reham, Jun Kishi, Masami Kishi, Katsuhiro Kinoshita, Hisanori Uehara, Keisuke Izumi and Saburo Sone : The role of sphingosine 1-phospate (SIP) signaling in pulmonary fibrosis., ATS 2011 International Conference, Denver, May 2011.
9.	Momoyo Azuma, Takada Shinsuke, Sato Seidai, Hisatsugu Goto, Hiroaki Yanagawa, Yasuhiko Nishioka, Kenichi Maeda, Shin-ichi Akiyama and Saburo Sone : Investigation of complementary and alternative medicine in lung cancer patients in Tokushima Univerity Hospital., 第9回アジア臨床腫瘍学会学術集会, Gifu, Aug. 2010.
10.	Kishi Masami, Yasuhiko Nishioka, Momoyo Azuma, Yoshinori Aono, Batmunkh Rentsenkhand, El-morshedy Mohammed Reham, Katsuhiro Kinoshita, Jun Kishi, Uehara Hisanori, Izumi Keisuke and Saburo Sone : Anifibrotic effects of APA5 and APB5, blocking antibodies specific for PDGF receptors on bleomycine-induced pulmonary fibrosis in mice., ATS 2010 International Conference, New Orleans, May 2010.
11.	Momoyo Azuma, Yasuhiko Nishioka, El-morshedy Mohammed Reham, Jun Kishi, Katsuhiro Kinoshita, Uehara Hisanori, Izumi Keisuke and Saburo Sone : Effects of the novel immunomodulatory sphingosine l-phospate(S1P) receptor agonist FTY720 in bleomycine-induced pulmonaty fibrosis in mice., ATS 2010 International Conference, New Orleans, May 2010.

Proceeding of Domestic Conference:

1.	Yu Aoi, Hiroki Bandoh, Keiko Haji, 高橋啓輝, Hiroto Yoneda, Akane Abe, Seidai Satou, Momoyo Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : 気管支鏡検査で診断したCOVID-19関連肺アスペルギルス症の1例, 第32回日本呼吸器内視鏡学会中国四国支部会, Dec. 2023.
2.	中西渓介, Hiroki Bandoh, Keiko Haji, 小倉祐一郎, 美馬正人, Nobuhito Naito, Akane Abe, 川真田純, 杉浦宏, Seidai Satou, Momoyo Azuma, Masaki Hanibuchi, Koichi Sairyo and Yasuhiko Nishioka : 結核性脊椎炎の治療中にparadoxical responseとして皮下膿瘍が出現した1例, 第74 回日本結核・非結核性抗酸菌症学会中国四国支部会, Dec. 2023.
3.	Akane Abe, Momoyo Azuma, 泉侑希 and Yasuhiko Nishioka : 当院におけるClostridioides difficile検査に対するDiagnostic stewardshipの取り組みの経過報告, 第97回日本感染症学会総会・学術講演会, Apr. 2023.
4.	Kenya Miyamoto, Keiko Haji, 原田紗希, 鈴江涼子, Akane Abe, Momoyo Azuma, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 当院における肺MAC症に対するアジスロマイシン併用療法の有効性・安全性の検討, 第73回日本結核・非結核性抗酸菌症学会中国四国支部会, Dec. 2022.
5.	Momoyo Azuma : ワクチンにおける知識のギャップ解消を目的とした教育効果の検討 ∼妊婦対象ワクチンについて∼, 第70 回日本化学療法学会総会, Jul. 2022.
6.	Momoyo Azuma : 各職種のDiagnostic stewardshipへのアプローチ.各職種のDSへのアプローチ ∼医師からのDSへのアプローチ∼, 第70 回日本化学療法学会総会/ワークショップ, Jul. 2022.
7.	Akane Abe, Momoyo Azuma, Naoto Okada, 佐藤雅美, 高橋真理, 矢野由美子 and Yasuhiko Nishioka : 当院における血液培養，Clostridioides difficile検査に対するDiagnostic stewardshipの取り組み, 第70回日本化学療法学会総会, Jun. 2022.
8.	Momoyo Azuma, Yasuhiko Nishioka, 森野紗衣子 and 大石和徳 : 65歳以上の成人に対するPCV13-PPSV23連続接種の安全性と免疫原性の検討, 第70回日本化学療法学会総会, Jun. 2022.
9.	森戸克弥, 島田明奈, 宮崎徹, 清水良多, 高橋尚子, Momoyo Azuma, 下澤伸行, Tatsuya Fukuta, Kentaro Kogure and Tamotsu Tanaka : X連鎖性副腎白質ジストロフィー患者血漿中セラミドの分析とその主要な分子種の動物細胞への取り込みと作用, 第63回日本生化学中国・四国支部例会, May 2022.
10.	Naoto Okada, Aki Nakamoto, 泉侑希, Masayuki Chuma, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, Yoshito Zamami, Momoyo Azuma and Keisuke Ishizawa : タゾバクタム・ピペラシリン併用時における血中濃度時間曲線下面積に基づくバンコマイシン誘発腎障害の評価, 第15回日本腎臓病薬物療法学会学術集会・総会2021, Nov. 2021.
11.	TSUJINAKA Kaito, Naoto Okada, 藤原範子, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, 櫻田巧, 桐野靖, Yoshito Zamami, Momoyo Azuma and Keisuke Ishizawa : 医療従事者におけるインフルエンザ暴露後予防目的におけるオセルタミビルのアドヒアランス解析, 第31回日本医療薬学会年会, Oct. 2021.
12.	Naoto Okada, Aki Nakamoto, 泉侑希, Masayuki Chuma, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, Yoshito Zamami, Momoyo Azuma and Keisuke Ishizawa : タゾバクタム・ピペラシリン併用時のバンコマイシン誘発腎障害は血中濃度時間曲線下面積を指標とした TDMによって回避可能か?, 第31回日本医療薬学会年会, Oct. 2021.
13.	Momoyo Azuma, Shingen Nakamura and 吉田志緒美 : ∼抗酸菌症にチームで立ち向かう∼最新の知見と新たな光∼ 無菌手洗い装置によるMycobacterium chimaeraの偽アウトブレイク, Japanese Journal of Chemotherapy, Vol.69, No.2, 177-178, Mar. 2021. (Keyword) Mycobacterium 抗酸菌症環境微生物学給水院内感染 *保菌者状態ヒト
14.	Momoyo Azuma, Shingen Nakamura and 吉田志緒美 : ~抗酸菌症にチームで立ち向かう~最新の知見と新たな光~ 無菌手洗い装置によるMycobacterium chimaeraの偽アウトブレイク, Japanese Journal of Chemotherapy, Vol.69, No.2, 177-178, Mar. 2021. (Keyword) Mycobacterium / 抗酸菌症 / 環境微生物学 / 給水 / 院内感染 / 保菌者状態 / ヒト
15.	南城和正, Mitsuteru Yoshida, Momoyo Azuma, 庄野隆志, 山本清成, Hidenori Maki, 宮本直輝, 坂本晋一, Mika Takashima, Daisuke Matsumoto, Naoya Kawakita, Hiroaki Toba, Yukikiyo Kawakami, Hiromitsu Takizawa and Akira Tangoku : 呼吸器外科からみた結核スクリーニング-T-SPOT検査は有用か-, 第73回日本胸部外科学会定期学術集会(Web開催), Oct. 2020.
16.	平岡栞名, 三井由加里, Hirokazu Miki, Seidai Satou, Momoyo Azuma, 遠藤ふうり, 宮髙紘輔, 辻誠士郎, 桝田志保, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 発熱・全身リンパ節腫脹で発症し，リンパ節生検で診断しえた結核性リンパ節炎の一例, 第261回徳島医学会学術集会, Aug. 2020.
17.	Ulfa Maria, Takaaki Shimohata, Shiho Fukushima, Masami Sato, Momoyo Azuma, Takashi Uebanso, Kazuaki Mawatari, Masatake Akutagawa, Yohsuke Kinouchi and Akira Takahashi : Effect of 365 nm LED on the inactivation of ESBL producing Escherichia coli, 日米医学協力研究会コレラ・細菌性腸管感染症専門部会, Aug. 2019.
18.	Naoko Takahashi, Ryota Shimizu, Katsuya Morito, Momoyo Azuma, Nobuyuki Shimozawa, Tatsuya Fukuta, Kentaro Kogure and Tamotsu Tanaka : 液体クロマトグラフィー/タンデム質量分析を用いた副腎白質ジストロフィー患者の血中セラミド分析, 第60回日本生化学中国・四国支部例会, May 2019.
19.	鈴木恵美, Mitsuteru Yoshida, Momoyo Azuma, Ryo Yamada, Daisuke Matsumoto, Mika Takashima, Toru Sawada, Naoya Kawakita, Mitsuhiro Tsuboi, Hiroaki Toba, Yukikiyo Kawakami, Hiromitsu Takizawa, Kazuya Kondo and Akira Tangoku : 呼吸器外科からみた結核スクリーニング-T-SPOT検査は有用であるか-, 第36回日本呼吸器外科学会総会, May 2019.
20.	Ulfa Maria, Takaaki Shimohata, Shiho Fukushima, Momoyo Azuma, Takashi Uebanso, Kazuaki Mawatari and Akira Takahashi : The effectiveness of UVA-LED irradiation on ESBL producing Escherichia coli, 第92回日本細菌学会総会, Apr. 2019.
21.	Hiroyasu Okazaki, Seidai Satou, Shun Morizumi, 小山壱也, Hirohisa Ogawa, Kozo Kagawa, 西村春佳, Chen Yajuan, Yoshinori Aono, Shuichi Abe, Momoyo Azuma, Hisatsugu Goto, Hiroshi Kawano, Yuko Toyoda, Hisanori Uehara, 小路弘行 and Yasuhiko Nishioka : ブレオマイシン肺線維症マウスモデルにおけるWnt/B-カテニン/CBPシグナル阻害薬PRI-724による抗線維化効果の検討, 第59回日本呼吸器学会学術講演会, Apr. 2019.
22.	Katsuya Morito, Akina Shimada, Tohru Miyazaki, Ryota Shimizu, Naoko Takahashi, Momoyo Azuma, Koyama Kazuya, Yasuhiko Nishioka, Tatsuya Fukuta, Kentaro Kogure and Tamotsu Tanaka : ヒト血漿中セラミド及びセラミド1-リン酸の分子種組成と動物細胞へ作用, 日本農芸化学会2019年度大会, Mar. 2019.
23.	Rina Murata, Keiji Murakami, Hideki Fujii, 佐藤雅美, 笹田倫子, 井上みなみ, 平尾早紀, 別所将弘, Momoyo Azuma, Akiko Sakurai and Keiko Kataoka : 呼吸器感染症患者由来緑膿菌の抗菌薬抵抗性と抗酸化能の関連について, 第42回徳島県医学検査学会, Dec. 2018.
24.	Katsuya Morito, Ryota Shimizu, Naoko Takahashi, 下澤伸行, Momoyo Azuma, Hiroshi Kawano, Yasuhiko Nishioka, Tatsuya Fukuta, Kentaro Kogure and Tamotsu Tanaka : ヒト血漿中セラミド及びセラミド1-リン酸の分子種組成と細胞への取り込み, 第91回日本生化学会大会, Sep. 2018.
25.	Ulfa Maria, Takaaki Shimohata, Shiho Fukushima, Momoyo Azuma, Takashi Uebanso, Kazuaki Mawatari and Akira Takahashi : Application of UVA-LED on Extended-Spectrumβ-Lactamase(ESBL) Producing Escherichia coli from Clinical Isolates, 第257回徳島医学会学術集会, Aug. 2018.
26.	Mitsuteru Yoshida, Momoyo Azuma, Toru Sawada, Naoya Kawakita, Mitsuhiro Tsuboi, Hiroaki Toba, Yukikiyo Kawakami, Hiromitsu Takizawa, Kazuya Kondo and Akira Tangoku : 《Oralセッション》結核スクリーニングにおけるT-SPOT測定-気管支鏡検査，胸腔鏡生検の役割-, 第41回日本呼吸器内視鏡学会学術集会, May 2018.
27.	Fujiwara Noriko, Satoh Masami, Keiji Murakami and Momoyo Azuma : 総合周産期母子医療センターにおける感染対策について, 第33回環境感染学会総会, Feb. 2018.
28.	清水良多, 山下量平, 伊賀永里奈, Rahman Motiur Md., Momoyo Azuma, Kentaro Kogure and Tamotsu Tanaka : 液体クロマトグラフィー/タンデム質量分析による血漿中のセラミド及びセラミド-1-リン酸の解析, 第58回日本生化学会中国・四国支部例会, May 2017.
29.	Shoto Ogawa, Shinichi Fujie, Keiji Murakami, Takashi Amoh, Yoichiro Miyake, 佐藤雅美, 笹田倫子, 菅崎幹樹, 香川葉子, Yuri Morimoto, Momoyo Azuma, Akiko Sakurai and Keiko Kataoka : 緑膿菌オートインデューサー類似化合物が抗菌薬抵抗性に及ぼす影響, 第40回徳島県医学検査学会, Dec. 2016.
30.	Hiroto Yoneda, Seidai Satou, Kohzoh Kagawa, Hirokazu Ogino, Satoshi Sakaguchi, Yuko Toyoda, Momoyo Azuma, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi and Yasuhiko Nishioka : 骨髄異形成症候群に播種性結核症を合併し治療に難渋した一例, 第66回日本結核病学会中国四国支部会, Dec. 2015.
31.	Ayumi Yoshida, Mai Ueta, Keiji Murakami, Yoichiro Miyake, 佐藤雅美, 笹田倫子, 菅崎幹樹, 香川葉子, Yuri Morimoto, Momoyo Azuma, Akiko Sakurai and Keiko Kataoka : 緑膿菌におけるストレス応答と抗菌薬抵抗性について, 第39回徳島県医学検査学会, Dec. 2015.
32.	Mai Ueta, Ayumi Yoshida, Keiji Murakami, Yoichiro Miyake, 佐藤雅美, 笹田倫子, 菅崎幹樹, 香川葉子, Yuri Morimoto, Momoyo Azuma, Akiko Sakurai and Keiko Kataoka : リボザイムを応用したcyclic-di-GMPの定量法の開発, 第39回徳島県医学検査学会, Dec. 2015.
33.	西迫寛隆, 中川博之, Momoyo Azuma, Naoto Okada, 上村卓広, 中村敏己, Kazuhiko Teraoka, Kazuyoshi Kawazoe and Keisuke Ishizawa : 当院におけるカンジダ血症治療に対するガイドライン遵守率向上への取り組み, 第54回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2015.
34.	Naoto Okada, 伏谷秀治, Momoyo Azuma, 中村敏己, Kazuhiko Teraoka, Kazuyoshi Kawazoe and Keisuke Ishizawa : 抗MRSA薬を用いた治療に対する薬剤師介入の有用性:プロトコルに基づく薬物治療管理と多職種介入による臨床効果及び医療経済効果, 第25回日本医療薬学会年会, Nov. 2015.
35.	Naoto Okada, 下岡幸恵, Momoyo Azuma and Keisuke Ishizawa : プロトコルに基づく薬物治療管理が医師の診療行動へ与える影響, 第63回日本化学療法学会総会, Jun. 2015.
36.	Shingen Nakamura, Momoyo Azuma, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe : 当院で経験した重症熱性血小板減少症候群の3例, 第89回日本感染症学会, Apr. 2015.
37.	Naoto Okada, 伏谷秀治, Momoyo Azuma, 中村敏己, Kazuhiko Teraoka, Kazuyoshi Kawazoe, Hiroyoshi Watanabe, Masahiro Abe and Keisuke Ishizawa : 病棟薬剤によるプロトコルに基づく薬物治療管理の実践∼抗MRSA薬の適正使用に対する効果∼, 日本薬学会第135年会, Mar. 2015.
38.	西迫寛隆, 中川博之, Momoyo Azuma, 下岡幸恵, 伏谷秀治, 中村敏己, Kazuhiko Teraoka, Kazuyoshi Kawazoe and Keisuke Ishizawa : 徳島大学病院における真菌感染BUNDLEの活用について, 日本薬学会第135年会, Mar. 2015.
39.	荻野広和, Yuko Toyoda, Mayuri Nakano, Momoyo Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : 皮膚筋炎に対してステロイドおよび免疫抑制剤による加療中に発症した播種性Mycobacterium avium症の1例, 第90回日本結核病学会総会, Mar. 2015.
40.	Naoto Okada, 伏谷秀治, Momoyo Azuma, 中村敏己, Kazuhiko Teraoka, Kazuyoshi Kawazoe, Hiroyoshi Watanabe, Masahiro Abe and Keisuke Ishizawa : 病棟薬剤によるプロトコルに基づく薬物治療管理の実践∼抗MRSA薬の適正使用に対する効果, 日本薬学会第135年会(神戸), Mar. 2015.
41.	Momoyo Azuma, Ken-ichiro Shimai, Shinsuke Katoh and 他 : 「HYDRO AG」を用いたタッチパネル液晶護フイルムの医療現場における有用性の検討, 第30回日本感染環境学会総会・学術集, Mar. 2015.
42.	Mayuri Nakano, Momoyo Azuma, Terumi Takikura, Satoshi Sakaguchi, Yuko Toyoda, 上回紗代, 安倍秀斉, Masaki Hanibuchi, Toshio Doi and Yasuhiko Nishioka : 長期間ステロイド投与が発症の契機となったMycobacterium intracellulareによる関節炎と骨髄炎の2症例, 第65回日本結核病学会中国四国支部会, Feb. 2015.
43.	Momoyo Azuma, 中曽亜佐美, 藤原範子, 畑美智子, Shinsuke Katoh and Yasuhiko Nishioka : 「HYDRO AG」を用いたタッチパネル液晶保護フィルムの医療現場における有用性の検討, 第30回日本環境感染学会総会・学術集会, Feb. 2015.
44.	丸橋朋子, Shingen Nakamura, 曽我部公子, 八木ひかる, 高橋真美子, 宇高憲吾, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe, Atsuro Saijo, Mayuri Nakano, Momoyo Azuma, Yasuhiko Nishioka, 近藤憲保, 井内新, 藤田博己 and 馬原文彦 : 当院で経験した重症熱性血小板減少症候群の3例, 第250回徳島医学会学術集会, Feb. 2015.
45.	野田和克, Momoyo Azuma, 西迫寛隆, 伏谷秀治, 佐藤雅美, 畑美智子, Keisuke Ishizawa and Yasuhiko Nishioka : 真菌感染BUNDLEの徳島大学病院での活用について, 第250回徳島医学会学術集会, Feb. 2015.
46.	Yukari Yoshikawa, Shoko Kannuki, Keiji Murakami, Yoichiro Miyake, 畑美智子, 佐藤雅美, 笹田倫子, 香川葉子, 菅崎幹樹, Momoyo Azuma, Akiko Sakurai and Keiko Kataoka : 本院で分離されたST-8型MRSAについて, 第38回徳島県医学検査学会, Dec. 2014.
47.	Shoko Kannuki, Yukari Yoshikawa, Keiji Murakami, Yoichiro Miyake, Hideaki Maseda, 畑美智子, 佐藤雅美, 笹田倫子, 香川葉子, 菅崎幹樹, Momoyo Azuma, Akiko Sakurai and Keiko Kataoka : 臨床および環境分離緑膿菌における病原性について, 第38回徳島県医学検査学会, Dec. 2014.
48.	Masaki Hanibuchi, 中曽亜佐美, 藤原範子, Momoyo Azuma and Yasuhiko Nishioka : 徳島大学病院における結核対策の現状, 第8回日本結核病学会中国四国支部研究会 (シンポジウム), Sep. 2014.
49.	塚﨑佑貴, 大塚憲司, 岸昌美, 近藤真代, 吉嶋輝実, Seidai Satou, 岡埼弘泰, 竹﨑彰夫, Momoyo Azuma, Masaki Hanibuchi, 坂下直美, 福田悠 and Yasuhiko Nishioka : Acute Fibrinous and Organizing Pneumonia (AFOP) の一剖検例, 第51回日本呼吸器学会中国・四国地方会, Jul. 2014.
50.	Momoyo Azuma and Yasuhiko Nishioka : 緑膿菌感染患者におけるTolerance とバイオフィルム形成能の検討, 第88回日本感染症学会学術講演会, Jun. 2014.
51.	Mayuri Nakano, 高橋直希, 吉嶋輝実, Atsuro Saijo, Toshifumi Tezuka, Momoyo Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : 当院で経験した重症熱性血小板減少症候群(severe fever with thrombocytopenia syndrome: SFTS)の1例, 第88回日本感染症学会学術講演会, Jun. 2014.
52.	岸昌美, Yoshinori Aono, Momoyo Azuma, Katsuhiro Kinoshita, Seidai Satou, 吉嶋輝実, 竹﨑彰夫 and Yasuhiko Nishioka : PDGFレセプター-α, β阻害抗体のブレオマイシン誘発肺線維症モデルマウスにおける抗線維化効果, 第54回日本呼吸器学会学術講演会, Apr. 2014.
53.	山本聖子, Masaki Hanibuchi, Shun Morizumi, Masami Kishi, Katsuhiro Kinoshita, Hiroshi Kawano, Akio Takezaki, Yuko Toyoda, Momoyo Azuma, Hisatsugu Goto, Jun Kishi and Yasuhiko Nishioka : 左上葉無気肺を呈したアレルギー性気管支肺アスペルギルス症の一例, 第248回徳島医学会, Feb. 2014.
54.	是松麻美, 内藤伸仁, 岸昌美, Mayuri Nakano, 吉田光輝, 川上行奎, Katsuhiro Kinoshita, Momoyo Azuma, 吉嶋輝実, 佐藤正大, Jun Kishi, 森河由里子, 松山友理子, 榊美佳, 坂東良美, 渡邉俊介, 上原久典, 泉啓介, 先山正二, Masaki Hanibuchi and Yasuhiko Nishioka : 胸水中に多数のLanghans型巨細胞を認めたMycobacterium avium症に伴う胸膜炎の一例., 第64回日本結核病学会中国四国支部会, Feb. 2014.
55.	Shingen Nakamura and Momoyo Azuma : 多発性骨髄腫におけるガラクトマンナン抗原検査の有用性, Kansenshōgaku Zasshi, 2014.
56.	山本聖子, Masaki Hanibuchi, Shun Morizumi, Masami Kishi, Katsuhiro Kinoshita, Hiroshi Kawano, Akio Takezaki, Yuko Toyoda, Momoyo Azuma, Hisatsugu Goto, Jun Kishi and Yasuhiko Nishioka : 左上葉無気肺を呈したアレルギー性気管支肺アスペルギルス症の一例., 第50回日本呼吸器学会中国・四国地方会, Dec. 2013.
57.	矢葺洋平, Atsuro Saijo, Katsuhiro Kinoshita, Momoyo Azuma, Hisatsugu Goto, Souji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka, 井内新, Yoshinori Aono, 福野天, 朝田完二, 長瀬教夫, 藤田博己 and 馬原文彦 : 徳島県で発生した重症熱性血小板減少症候群 (severe fever with thrombocytopenia syndrome: SFTS) の1例, 第247回徳島医学会学術集会, Aug. 2013.
58.	Asami Korematsu, Masami Kishi, Yoshinori Aono, Akio Takezaki, Momoyo Azuma, Katsuhiro Kinoshita, Shuichi Abe, Masaki Hanibuchi, Mitsuteru Yoshida, Shoji Sakiyama, 福田悠 and Yasuhiko Nishioka : 徳島大学病院における胸腔鏡 (VATS)下肺生検症例の検討, 第49回日本呼吸器学会中国・四国地方会, Jul. 2013.
59.	Momoyo Azuma : 徳島大学病院における耐性菌の現状, 地球規模課題対応国際科学技術プログラム(SATREPS) 「薬剤耐性細菌発生機構の解明と食品管理における耐性菌モニタリングシステムの開発」に係る研究会, Jul. 2013.
60.	Naoki Takahashi, Masaki Hanibuchi, Yoshinori Aono, Katsuhiro Kinoshita, Momoyo Azuma, Masami Kishi, Akio Takezaki, Atsuro Saijo, Hisatsugu Goto and Yasuhiko Nishioka : 当院におけるidiopathic pleuroparenchymal fibroelastosis (IPPFE) 症例の検討, 第108回日本内科学会四国地方会, Jun. 2013.
61.	阿部秀一, Yoshinori Aono, 岡﨑弘泰, 岸昌美, 竹﨑彰夫, Katsuhiro Kinoshita, Momoyo Azuma, Jun Kishi and Yasuhiko Nishioka : 肺線維症における増殖因子産生を介したfibrocyteの役割と検討., 第53回日本呼吸器学会学術講演会, Apr. 2013.
62.	Terumi Yoshijima, Masaki Hanibuchi, Momoyo Azuma, Yuko Toyoda, Hiroshi Kawano, Jun Kishi, Akio Takezaki, Hiroyasu Okazaki, Tamiko Nagao, Reiko Suzuki, Tomoko Takagai, Shoji Sakiyama and Yasuhiko Nishioka : 徳島大学病院職員における潜在性結核感染症の現状, 第63回日本結核病学会中国四国支部会, Feb. 2013.
63.	Hanako Matsuda, Hiroshi Kawano, Jun Kishi, Yoshinori Aono, Kozo Kagawa, Hiroto Yoneda, Hiroyasu Okazaki, Akio Takezaki, Momoyo Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : ステロイド抵抗性器質化肺炎の加療中に気胸・肺血栓塞栓症を合併した1例, 第48回日本呼吸器学会中国・四国地方会, Dec. 2012.
64.	Masaki Hanibuchi, Tamiko Nagao, Reiko Suzuki, Tomoko Takagai, Momoyo Azuma, Shoji Sakiyama and Yasuhiko Nishioka : 潜在性結核感染症 (latent tuberculosis infection: LTBI) に対する治療の現状と問題点, 第6回日本結核病学会中国四国支部研究会, Sep. 2012.
65.	Shuichi Abe, Hiroyasu Okazaki, Masami Kishi, Akio Takezzaki, Katsuhiro Kinoshita, Momoyo Azuma, Jun Kishi, Yoshinori Aono and Yasuhiko Nishioka : Fibrocyteの肺線維芽細胞機能に及ぼす効果の検討, 第52回日本呼吸器学会学術講演会, Apr. 2012.
66.	Kishi Masami, Yoshinori Aono, Takezaki Akio, Momoyo Azuma, Jun Kishi and Yasuhiko Nishioka : 当院におけるピルフェニドン投与症例の検討, 第52回日本呼吸器学会学術講演会, Apr. 2012.
67.	Mayo Kondo, Yuko Toyoda, Shuichi Abe, Hiroshi Kawano, Masami Kishi, Akio Takezaki, Momoyo Azuma, Souji Kakiuchi, Hisatsugu Goto, Yoshinori Aono, Masaki Hanibuchi and Yasuhiko Nishioka : 病勢に関連してCA19-9の変動を認めた非結核性抗酸菌症の1例, 第20回日本呼吸器内視鏡学会中国四国支部会, Mar. 2012.
68.	Hiroyuki Kozai, Toshifumi Tezuka, Hiroshi Kawano, Akio Takezaski, Momoyo Azuma, Souji Kakiuchi, Hisatsugu Goto, Jun Kishi, Yoshinori Aono, Masaki Hanibuchi and Yasuhiko Nishioka : 非結核性抗酸菌症を合併したサルコイドーシスの1例, 第20回日本呼吸器内視鏡学会中国四国支部会, Mar. 2012.
69.	長尾多美子, 高開登茂子, Momoyo Azuma, Keiji Murakami and Shoji Sakiyama : 大学病院での百日咳疑いアウトブレイクを経験して, 第27回日本環境感染学会総会, Feb. 2012.
70.	Keiji Murakami, Momoyo Azuma, 畑美智子, 長尾多美子, 高開登茂子 and Shoji Sakiyama : 緑膿菌臨床分離株における薬剤耐性とバイオフィルム形成について, 第27回日本環境感染学会総会, Feb. 2012.
71.	高橋直希, 飛梅亮, Toshifumi Tezuka, Yuko Toyoda, Momoyo Azuma, Hisatsugu Goto, Souji Kakiuchi, Jun Kishi, Yoshinori Aono, Masaki Hanibuchi, Masahiko Azuma, Saburo Sone, Yasuhiko Nishioka, 高橋美紀子 and 福田悠 : 間質性肺炎の精査により診断されたIgG4関連疾患の1例, 第46回日本呼吸器学会中国・四国地方会, Jul. 2011.
72.	竹﨑彰夫, Momoyo Azuma, 木下勝弘, Hisatsugu Goto, 多田浩也, 吾妻雅彦, Yasuhiko Nishioka and Saburo Sone : 当院における慢性壊死性肺アスペルギルス症に対するアムビゾームの使用経験．, 第51回日本呼吸器学会学術講演会, Apr. 2011.
73.	木下勝弘, Yasuhiko Nishioka, 岸昌美, Momoyo Azuma, Yoshinori Aono, 竹﨑彰夫, 上原久典, 畠山慎二, 河原英治 and Saburo Sone : ブレオマイシン肺線維症モデルにおけるFAK阻害剤TAE226の抗線維化効果の検討．, 第51回日本呼吸器学会学術講演会, Apr. 2011.
74.	Momoyo Azuma, Yasuhiko Nishioka, Reham Elmorshedy Mohammed, Jun Kishi, 岸昌美, 木下勝弘, 竹崎彰夫, Huang Jun, 上原久典, 泉啓介, 秋山伸一 and Saburo Sone : 肺線維症におけるスフィンゴシン-1-リン酸シグナルの検討．, 第51回日本呼吸器学会学術講演会, Apr. 2011.
75.	仁木昌徳, Atsuro Saijo, Hisatsugu Goto, 本淨晃史, Katsuhiro Kinoshita, Momoyo Azuma, 多田浩也, 吾妻雅彦, Yasuhiko Nishioka and Saburo Sone : Clarithromycin，Amikacin，Imipenem/cilastatin，Moxifloxacinの併用療法が有効であった肺Mycobacterium abscessus感染症の1例．, 第19回日本呼吸器内視鏡学会中国四国支部会, Jan. 2011.
76.	阿部秀一, Toshifumi Tezuka, Katsuhiro Kinoshita, Momoyo Azuma, 多田浩也, Yasuhiko Nishioka and Saburo Sone : 徳島大学病院における呼吸器検体から分離された薬剤耐性肺炎球菌の動向について., 第50回日本呼吸器学会学術講演会, Apr. 2010.
77.	Momoyo Azuma, Mohammed Reham Elmorshedy, Jun Kishi, Katsuhiro Kinoshita, 岸昌美, Yasuhiko Nishioka and Saburo Sone : 新規免疫抑制薬フィンゴリモド(FTY720)のマウスブレオマイシン誘発肺線維症に及ぼす効果の検討., 第50回日本呼吸器学会学術講演会, Apr. 2010.
78.	岸昌美, Yasuhiko Nishioka, Momoyo Azuma, 木下勝弘, Jun Kishi and Saburo Sone : ブレオマイシン誘発肺線維症モデルマウスにおけるPDGFレセプターα，β阻害抗体の抗線維化効果., 第50回日本呼吸器学会学術講演会, Apr. 2010.
79.	Yuko Toyoda, Momoyo Azuma, Hisatsugu Goto, Yoshinori Aono, Rentsenhand Batmungh, Yasuhiko Nishioka and Saburo Sone : 放射線治療後の乳癌患者に発症した器質化肺炎におけるBALFの臨床的検討．, 第18回日本呼吸器内視鏡学会中国四国支部会, Feb. 2010.

Et cetera, Workshop:

1.	Shinichi Fujie, Shoto Ogawa, Keiji Murakami, Takashi Amoh, Yoichiro Miyake, 佐藤雅美, 笹田倫子, 菅崎幹樹, 香川葉子, Yuri Morimoto, Momoyo Azuma, Akiko Sakurai and Keiko Kataoka : 呼吸器由来緑膿菌における病原性と抗菌薬抵抗性との関連について, 第40回徳島県医学検査学会, Dec. 2016.
2.	Keiko Kataoka, 南亜利沙, Keiji Murakami, Yoichiro Miyake, 畑美智子, 佐藤雅美, 岡本貴子, 香川葉子, 菅崎幹樹 and Momoyo Azuma : 本院で分離されたMRSAの分類とその特徴, 徳島県医学検査学会, Dec. 2013.
3.	Keiko Kataoka, 堀口なつみ, Keiji Murakami, Yoichiro Miyake, 畑美智子, 佐藤雅美, 岡本貴子, 香川葉子, 菅崎幹樹 and Momoyo Azuma : 「緑膿菌臨床分離株における抗菌薬抵抗性について」, 徳島県医学検査学会, Dec. 2013.
4.	Keiji Murakami, Momoyo Azuma, 畑美智子, 長尾多美子, 鈴木麗子, Yoichiro Miyake and Shoji Sakiyama : 徳島大学病院におけるパルスフィールドゲル電気泳動法(PFGE)によるMRSAの分子疫学調査, 第4回MRSAフォーラム, Jul. 2013.
5.	岸昌美, Yasuhiko Nishioka, Katsuhiro Kinoshita, Momoyo Azuma, 竹﨑彰夫 and Saburo Sone : ピルフェドニンが著効した肝硬変合併症IPFの一例．, 厚生労働科学研究難治性疾患克服研究事業びまん性肺疾患に関する調査研究班平成22年度第2回班会議総会, Dec. 2010.

Report:

1.	Yasuhiko Nishioka, Momoyo Azuma, Katsuhiro Kinoshita, 岸昌美, 竹﨑彰夫 and Saburo Sone : 肺線維症におけるスフィンゴシン-1-リン酸シグナルの検討, 難治生疾患克服研究事業びまん性肺疾患に関する調査研究平成22年度研究報告書, 315-319, Mar. 2011.
2.	Yasuhiko Nishioka, 岸昌美, Yoshinori Aono, Momoyo Azuma and Saburo Sone : ブレオマイシン誘発肺線維症モデルマウスにおけるPDGFレセプターα，β阻害抗体の抗繊維化効果, 難治性疾患克服研究事業びまん性肺疾患に関する調査研究班平成21年度報告書, 29-234, Mar. 2010.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

A new strategy for treatment of lung fibrosis; Identification of a complementary peptide which inhibited PDGF/PDGFR signaling pathway (Project/Area Number: 25461160 )
The role of S1P signaling in-pulmonary fibrosis, and S1PR1-S1P pathway may be an effective molecular therapeutic strategy for fibrotic lung disease (Project/Area Number: 23790909 )
Development of inhaled therapy with anti-fibrotic peptides for pulmonary fibrosis (Project/Area Number: 23659434 )
The role of CCN family signaling in pulmonary fibrosis, and CCN pathway may be an effective molecular therapeutic strategy for fibrotic lung disease (Project/Area Number: 21790772 )
Search by Researcher Number (10403750)

Associate Professor : Azuma, Momoyo

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Report:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)